Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal

Hisamitsu Pharmaceutical Co.’s ¥457 billion ($2.9 billion) plan to go private is being seen as a prime example of a flight from public markets among Japan’s drugmakers, with analysts expecting more to follow....

Redirecting to full article...